non-PH (n = 18) | PH (n = 41) | T/Z/χ2 | P | |
---|---|---|---|---|
Age (year) | 48.22 ± 17.96 | 47.65 ± 14.91 | 0.128† | 0.898 |
Sex (male/female) | 7 / 11 | 10 / 31 | 1.282§ | 0.258 |
Signs | ||||
aortic diastolic blood pressure (mmHg) | 75.78 ± 11.09 | 77.67 ± 10.97 | -0.614† | 0.542 |
aortic systolic blood pressure (mmHg) | 126.28 ± 21.43 | 116.98 ± 16.42 | 1.840† | 0.071 |
respiratory rate (times/min) | 18 (18~20) | 20.00 (19~20) | -2.083‡ | 0.037 |
pulse (times/min) | 80 (71.5~84) | 82.5 (72.75~91.75) | -1.401‡ | 0.161 |
Symptoms | ||||
dyspnea (%) | 4 (22.2%) | 36 (83.6%) | 24.642§ | < 0.001 |
fever (%) | 1 (5.6%) | 0 (0%) | - | 0.295 |
dizzy (%) | 8 (44.4%) | 0 (0%) | - | < 0.001 |
edema of both lower limbs (%) | 1 (5.6%) | 1 (2.3%) | - | 0.507 |
chest pain (%) | 1 (5.6%) | 1 (2.3%) | - | 0.507 |
palpitation (%) | 0 (0%) | 2 (4.7%) | - | 1.000 |
syncope (%) | 1 (5.6%) | 2 (4.7%) | - | 1.000 |
Medical history | ||||
congenital heart disease (%) | 12 (66.7%) | 10 (24.4%) | 9.560§ | 0.002 |
acute pulmonary embolism (%) | 2 (11.1%) | 20 (48.7%) | - | 0.008 |
chronic obstructive lung disease (%) | 0 (0%) | 3 (7.0%) | - | 0.548 |
coronary heart disease (%) | 3 (16.7%) | 11(26.8%) | - | 0.516 |
rheumatic disease (%) | 0 (0%) | 1 (2.3%) | - | 1.000 |
Group according to 2022 ESC/ERS guidelines | ||||
Group 1 (male/female) | NA | 11(1/10) | NA | NA |
Group 2 (male/female) | NA | 8(3/5) | NA | NA |
Group 3 (male/female) | NA | 2(0/2) | NA | NA |
Group 4 (male/female) | NA | 17(4/13) | NA | NA |
Group 5 (male/female) | NA | 3(2/1)a | NA | NA |